X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IMC-001 is a PD-L1 antibody, an immune checkpoint inhibitor. This antibody activates the anticancer functions of T cells by strongly inhibiting the binding between PD-1 expressed on T cells and PD-L1 expressed on the surface of cancer cells.
Lead Product(s): IMC-001
Therapeutic Area: Oncology Product Name: IMC-001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022
Details:
The agreement includes uses of IMC-002 for oncology indication as a monotherapy or combination agent in the Territory of Greater China (Mainland China, Hong Kong, Macau, and Taiwan).
Lead Product(s): IgG4 monoclonal antibody
Therapeutic Area: Oncology Product Name: IMC-002
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: 3D Medicines Corporation
Deal Size: $470.0 million Upfront Cash: $8.0 million
Deal Type: Collaboration March 31, 2021
Details:
Samsung Biologics will provide a full scope of CDO services from cell line development, process development, non-clinical and clinical material manufacturing, to IND submission support for global clinical trials of five candidates from ImmuneOncia's pipeline.
Lead Product(s): IMC-002
Therapeutic Area: Oncology Product Name: IMC-002
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Samsung Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
